Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

112.21
-0.0300-0.03%
Post-market: 112.210.00000.00%19:35 EDT
Volume:700.76K
Turnover:78.67M
Market Cap:5.52B
PE:-18.72
High:114.01
Open:113.10
Low:111.13
Close:112.24
Loading ...

BUZZ-Axsome Therapeutics rises on migraine drug trial data

Reuters
·
24 Feb

Axsome Therapeutics Price Target Maintained With a $153.00/Share by Needham

Dow Jones
·
24 Feb

Axsome Therapeutics Says Migraine Drug Symbravo Achieves Primary Endpoint in Phase 3 Trial

MT Newswires Live
·
24 Feb

Axsome Therapeutics says SYMBRAVO achieves primary endpoint in EMERGE trial

TIPRANKS
·
24 Feb

Axsome Therapeutics Inc - Symbravo Shows Greater Migraine Treatment Response Than Oral Cgrp Inhibitors

THOMSON REUTERS
·
24 Feb

Axsome Therapeutics Announces Symbravo® (Meloxicam and Rizatriptan) Achieves Primary Endpoint in the Emerge Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral Cgrp Inhibitors

THOMSON REUTERS
·
24 Feb

Axsome Therapeutics Inc - Symbravo Well Tolerated With Consistent Safety Profile

THOMSON REUTERS
·
24 Feb

Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors

GlobeNewswire
·
24 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intra-Cellular Therapies (ITCI), Axsome Therapeutics (AXSM) and Merck & Company (MRK)

TIPRANKS
·
24 Feb

Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025

Insider Monkey
·
24 Feb

Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Walgreens Boots Alliance (WBA) and Axsome Therapeutics (AXSM)

TIPRANKS
·
23 Feb

Stock Track | Axsome Therapeutics Soars 5.02% as Analyst Cites Optimistic Long-Term Prospects

Stock Track
·
22 Feb

Optimistic Long-Term Prospects for Axsome Therapeutics Amid Strong Sales and Strategic Pipeline Developments

TIPRANKS
·
21 Feb

Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025

Insider Monkey
·
20 Feb

Axsome Therapeutics Price Target Maintained With a $153.00/Share by Cantor Fitzgerald

Dow Jones
·
19 Feb

Axsome Therapeutics Inc : Piper Sandler Raises Target Price to $148 From $117

THOMSON REUTERS
·
19 Feb

Axsome Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
19 Feb

Axsome Therapeutics price target raised to $195 from $135 at Guggenheim

TIPRANKS
·
19 Feb

Analysts’ Top Healthcare Picks: Axsome Therapeutics (AXSM), Abbott Laboratories (ABT)

TIPRANKS
·
19 Feb

U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Penumbra, Republic Services

Reuters
·
19 Feb